About the Global AR Lab & Response Network

CDC’s Global Antimicrobial Resistance Laboratory and Response Network (Global AR Lab & Response Network) supports partners with experience in detecting and responding to antimicrobial resistance across the One Health spectrum.

Resistant bacteria and fungi can spread across countries and continents through people, animals, and goods. However, we don’t always know when and where these germs emerge and how they spread. CDC’s Global AR Lab & Response Network addresses a critical gap for a collaborative global approach to better detect and respond to antimicrobial resistance threats across the world.

Every country has varying levels of resources and might face different antimicrobial resistance threats. For example, some countries have a limited capacity to diagnose and track antimicrobial-resistant germs in healthcare facilities, which adds to the difficulty of implementing effective treatment and prevention programs.

The Global AR Lab & Response Network improves the detection of existing and emerging antimicrobial resistance threats and identifies risk factors that drive the emergence and spread of resistance across health care, the community, and the environment. This global network also supports response to these threats and informs global prevention strategies for antimicrobial resistance. This work will

• Improve patient outcomes and public health
• Reduce illness and death
• Lower healthcare costs

In 2022, more than 24 partners have implemented collaborations in more than 42 countries to launch the Global AR Lab & Response Network, tackling threats like:

• Azole-resistant Aspergillus fumigatus
• Bordetella pertussis
• Candida auris
• Carbapenem-resistant Enterobacterales
• Neisseria gonorrhoeae (gonorrhea)
• Neisseria meningitidis
• Salmonella Typhi and non-Typhi, and other resistant diarrheal pathogens
• Streptococcus pneumoniae